|
1
|
Kigawa J: New strategy for overcoming
resistance to chemotherapy of ovarian cancer. Yonago Acta Med.
56:43–50. 2013.PubMed/NCBI
|
|
2
|
Miles GD, Seiler M, Rodriguez L, Rajagopal
G and Bhanot G: Identifying microRNA/mRNA dysregulations in ovarian
cancer. BMC Res Notes. 5:1642012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ozols RF: Treatment goals in ovarian
cancer. Int J Gynecol Cancer. 15(Suppl 1): 3–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Davila M, Frost AR, Grizzle WE and
Chakrabarti R: LIM kinase 1 is essential for the invasive growth of
prostate epithelial cells: implications in prostate cancer. J Biol
Chem. 278:36868–36875. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou Y, Su J, Shi L, Liao Q and Su Q: DADS
downregulates the Rac1-ROCK1/PAK1-LIMK1-ADF/cofilin signaling
pathway, inhibiting cell migration and invasion. Oncol Rep.
29:605–612. 2013.PubMed/NCBI
|
|
6
|
Nishimura Y, Yoshioka K, Bernard O,
Bereczky B and Itoh K: A role of LIM kinase 1/cofilin pathway in
regulating endocytic trafficking of EGF receptor in human breast
cancer cells. Histochem Cell Biol. 126:627–638. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Q, Jiao D, Hu H, et al:
Downregulation of LIMK1 level inhibits migration of lung cancer
cells and enhances sensitivity to chemotherapy drugs. Oncol Res.
20:491–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jang I, Jeon BT, Jeong EA, et al:
Pak1/LIMK1/Cofilin pathway contributes to tumor migration and
invasion in human non-small sell lung sarcinomas and sell lines.
Korean J Physiol Pharmacol. 16:159–165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang W, Gan N and Zhou J:
Immunohistochemical investigation of the correlation between LIM
kinase 1 expression and development and progression of human
ovarian carcinoma. J Int Med Res. 40:1067–1073. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin H, Dai T, Xiong H, et al: Unregulated
miR-96 induces cell proliferation in human breast cancer by
downregulating transcriptional factor FOXO3a. PloS One.
5:e157972010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Zhang H, Zhao M, et al: MiR-138
inhibits tumor growth through repression of EZH2 in non-small cell
lung cancer. Cell Physiol Biochem. 31:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin Y, Chen D, Cabay RJ, Wang A, Crowe DL
and Zhou X: Role of microRNA-138 as a potential tumor suppressor in
head and neck squamous cell carcinoma. Int Rev Cell Mol Biol.
303:357–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu X, Jiang L, Wang A, Yu J, Shi F and
Zhou X: MicroRNA-138 suppresses invasion and promotes apoptosis in
head and neck squamous cell carcinoma cell lines. Cancer Lett.
286:217–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu X, Wang C, Chen Z, et al: MicroRNA-138
suppresses epithelial-mesenchymal transition in squamous cell
carcinoma cell lines. Biochem J. 440:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
MiR-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gong H, Song L, Lin C, et al:
Downregulation of miR-138 sustains NF-kappaB activation and
promotes lipid raft formation in esophageal squamous cell
carcinoma. Clin Cancer Res. 19:1083–1093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Long L, Huang G, Zhu H, Guo Y, Liu Y and
Huo J: Down-regulation of miR-138 promotes colorectal cancer
metastasis via directly targeting TWIST2. J Transl Med. 11:2752013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Q, Tang H, Yin S and Dong C:
Downregulation of microRNA-138 enhances the proliferation,
migration and invasion of cholangiocarcinoma cells through the
upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep. 29:2046–2052.
2013.PubMed/NCBI
|
|
19
|
Yeh YM, Chuang CM, Chao KC and Wang LH:
MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis
by targeting SOX4 and HIF-1alpha. Int J Cancer. 133:867–878. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wan L, Zhang L, Fan K and Wang J: miR-27b
targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol
Cell Biochem. 390:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang HS, Zhao JW, Wang H, et al: LIM
kinase 1 is required for insulin-dependent cell growth of
osteosarcoma cell lines. Mol Med Rep. 9:103–108. 2014.PubMed/NCBI
|
|
22
|
Manetti F: Recent findings confirm LIM
domain kinases as emerging target candidates for cancer therapy.
Curr Cancer Drug Targets. 12:543–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Golubovskaya VM, Sumbler B, Ho B, Yemma M
and Cance WG: MiR-138 and MiR-135 directly target focal adhesion
kinase, inhibit cell invasion, and increase sensitivity to
chemotherapy in cancer cells. Anticancer Agents Med Chem. 14:18–28.
2014. View Article : Google Scholar : PubMed/NCBI
|
